The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1308
ISSUE1308
March 23, 2009
Dexlansoprazole (Kapidex) for GERD and Erosive Esophagitis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Dexlansoprazole (Kapidex) for GERD and Erosive Esophagitis
March 23, 2009 (Issue: 1308)
The FDA has approved the proton-pump inhibitor (PPI) dexlansoprazole (Kapidex - Takeda), a delayed release formulation of the R-enantiomer of lansoprazole (Prevacid - Takeda), for treating and maintaining healing of erosive esophagitis and for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.